OCUPHIRE PHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.685 USD | -2.88% |
|
-2.03% | -44.02% |
| 05-10 | Ocuphire Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-11 | Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment | MT |
Chart calendar Ocuphire Pharma, Inc.
7231741f736e.yxDGm1YyLkYVh743Kt3_5ln0RFoF-3NNivZaEU5raP8.qSWI4SFIFy9068oPUL6-oRG1FxM8lEIl7rtoWx4eDaedYKvRIFhcJyD_yQ~a9fd262ab40eef0c83925e62112811f0
Upcoming events on Ocuphire Pharma, Inc.
Past events on Ocuphire Pharma, Inc.
| 10/05/2024 13:00 | Q1 2024 Earnings Release |
| 08/05/2024 20:00 | Aegis Capital Virtual Conference |
| 06/05/2024 00:00 | Association for Research in Vision and Ophthalmology Meeting - Presentation Number: 658 |
| 20/03/2024 14:00 | Wet AMD & Diabetic Eye Disease Drug Development Summit |
| 08/03/2024 13:00 | Q4 2023 Earnings Release |
| 27/02/2024 19:45 | BIO CEO & Investor Conference |
| 02/02/2024 | Angiogenesis, Exudation, and Degeneration Conference |
| 05/12/2023 15:00 | Business Update Call |
| 13/11/2023 13:00 | Q3 2023 Earnings Release |
| 04/11/2023 18:54 | American Academy Of Ophthalmology Meeting - Session: PA015 |
| 02/11/2023 | American Academy Of Ophthalmology Meeting - Session: PO456 |
| 02/11/2023 | American Academy Of Ophthalmology Meeting - Session:PO020 |
| 02/11/2023 20:19 | Eyecelerator AAO Retina Showcase |
| 13/10/2023 19:59 | The Retina Society Scientific Meeting |
| 10/10/2023 18:45 | JonesTrading Healthcare Summit |
| 07/10/2023 14:55 | Euretina Congress |
| 26/09/2023 18:35 | Cantor Global Healthcare Conference |
| 11/09/2023 16:00 | European Society of Cataract and Refractive Surgeons Congress - Abstract No.: FP23.05 |
| 11/09/2023 16:00 | European Society of Cataract & Refractive Surgeons Congress - Abstract Number: FP23.05 |
| 11/09/2023 12:36 | European Society of Cataract & Refractive Surgeons Congress - Abstract Number: FP23.06 |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 1,18 - | 0,59 0,47 24.42% | 39,9 28,1 42.03% | 19,0 23,9 -20.31% | 7,98 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | -20,8 -20,6 -0.69% | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -20,0 -8,85 -125.68% | -22,7 -21,8 -3.96% | 18,2 6,20 194.15% | -10,6 -5,46 -93.64% | -29,2 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | -56,7 -53,1 -6.8% | 18,2 15,6 16.88% | -9,97 -5,34 -86.94% | -7,17 |
|
Net income Million USD | Released Forecast Spread | -6,17 | 0,00 0,00 - | -56,7 -55,5 -2.13% | 17,9 14,7 22.01% | -9,99 -5,34 -87% | -7,17 |
|
EPS USD | Released Forecast Spread | -2,29 | 0,00 0,00 - | -3,82 -3,73 -2.48% | 0,87 0,74 18.1% | -0,46 -0,25 -84% | -0,29 |
| Announcement Date | 16/09/20 | 11/03/21 | 24/03/22 | 30/03/23 | 08/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 39,9 28,1 42.03% | 1,75 2,94 -40.5% | 3,67 2,28 61.03% | 11,9 2,91 310.63% | 1,69 5,96 -71.64% | 1,71 4,67 -63.36% | 2,03 | 2,06 | 2,18 | 2,00 |
|
EBITDA Million USD | Released Forecast Spread | -5,67 -5,38 -5.49% | -6,06 -5,10 -18.86% | -4,49 -5,88 23.54% | -4,04 -5,88 31.17% | ||||||||||
|
EBIT Million USD | Released Forecast Spread | -6,15 -5,16 -19.22% | -6,51 -6,25 -4.13% | -4,94 -6,65 25.7% | -4,54 -5,87 22.7% | 34,2 22,2 54.21% | -6,13 -3,20 -91.73% | -5,39 -5,11 -5.55% | 6,39 -4,94 229.22% | -5,43 -1,25 -334.58% | -7,71 -3,55 -117.43% | -7,22 | -7,19 | -7,07 | |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -6,31 -2,70 -133.73% | -6,60 -6,01 -9.82% | -4,93 -6,43 23.4% | -4,53 -5,78 21.58% | 34,3 31,6 8.37% | -5,79 -3,17 -82.7% | -4,96 -5,67 12.51% | 5,58 -5,05 210.44% | -4,80 -0,15 -3083.78% | -7,11 -3,24 -119.63% | -3,96 | -3,88 | 6,40 | |
|
Net income Million USD | Released Forecast Spread | -6,31 -4,56 -38.31% | -6,60 -6,01 -9.82% | -4,93 -6,59 25.22% | -4,53 -5,96 23.95% | 33,9 29,6 14.77% | -5,79 -3,17 -82.7% | -4,96 -5,67 12.51% | 5,56 -5,05 210.16% | -4,80 -0,15 -3082.45% | -7,11 -3,24 -119.63% | -3,96 | -3,88 | 6,40 | |
|
EPS USD | Released Forecast Spread | -0,18 -0,26 30.77% | -0,35 -0,35 0% | -0,25 -0,33 24.24% | -0,22 -0,30 26.67% | 1,69 1,43 17.91% | -0,28 -0,15 -86.67% | -0,24 -0,27 11.11% | 0,25 -0,24 204.17% | -0,21 0,00 -6206.31% | -0,29 -0,14 -114.81% | -0,16 | -0,16 | 0,27 | |
| Announcement Date | 24/03/22 | 13/05/22 | 12/08/22 | 04/11/22 | 30/03/23 | 15/05/23 | 11/08/23 | 13/11/23 | 08/03/24 | 10/05/24 | - | - | - | - |
More events
Past sector events for Ocuphire Pharma, Inc.
| 17/05/2024 13:52 | J. B. CHEMICALS & PHARMACEUTICALS LIMITED: Q4 2024 Earnings Release |
| 17/05/2024 09:28 | GLAXOSMITHKLINE PHARMACEUTICALS LIMITED: Q4 2024 Earnings Release |
| 15/05/2024 15:05 | MANKIND PHARMA LIMITED: Q4 2024 Earnings Release |
| 15/05/2024 06:30 | DERMAPHARM HOLDING SE: Q1 2024 Earnings Release |
| 15/05/2024 12:40 | CRESCO LABS INC.: Q1 2024 Earnings Release |
| 15/05/2024 08:03 | GRANULES INDIA LIMITED: Q4 2024 Earnings Release |
| 14/05/2024 | EISAI CO., LTD.: Q4 2023 Earnings Release |
| 14/05/2024 22:43 | LIQUIDIA CORPORATION: Q1 2024 Earnings Release |
| 14/05/2024 09:52 | BORA PHARMACEUTICALS CO., LTD.: Q1 2024 Earnings Release |
| 14/05/2024 06:30 | BAYER AG: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- OCUP Stock
- Calendar Ocuphire Pharma, Inc.
